Clinical, pathologic or molecular feature | Total N | Mean | Standard deviation | P value^ |
---|---|---|---|---|
All cases | 869 | 61.4 | 9.6 | Â |
Sex | Â | Â | Â | 0.19 |
Men | 394 (45%) | 61.0 | 9.0 | Â |
Women | 475 (55%) | 61.8 | 10.1 | Â |
Age (years) | Â | Â | Â | 0.35 |
< 60 | 196 (23%) | 60.5 | 10.5 | Â |
60-69 | 363 (42%) | 61.7 | 8.7 | Â |
≥70 | 310 (36%) | 61.5 | 9.9 |  |
Body mass index (BMI, kg/m2) | Â | Â | Â | 0.96 |
< 30 | 667 (83%) | 61.3 | 9.5 | Â |
≥30 | 141 (17%) | 61.4 | 9.1 |  |
Family history of colorectal cancer | Â | Â | Â | 0.005 |
(-) | 657 (76%) | 61.9 | 9.6 | Â |
(+) | 212 (24%) | 59.7 | 9.1 | Â |
Smoking status | Â | Â | Â | 0.99 |
Never | 350 (41%) | 61.4 | 10.1 | Â |
Past or current | 508 (59%) | 61.3 | 9.2 | Â |
Tumor location | Â | Â | Â | 0.024 |
Proximal colon (cecum to transverse) | 370 (44%) | 61.9 | 9.2 | Â |
Distal colon (splenic flexure to sigmoid) | 274 (33%) | 60.1 | 9.7 | Â |
Rectum | 192 (23%) | 62.3 | 9.4 | Â |
Disease stage | Â | Â | Â | 0.015 |
I | 196 (25%) | 61.5 | 9.2 | Â |
II | 253 (33%) | 62.5 | 9.2 | Â |
III | 226 (29%) | 60.1 | 9.5 | Â |
IV | 103 (13%) | 60.0 | 11.0 | Â |
Tumor grade | Â | Â | Â | 0.43 |
Low | 777 (91%) | 61.3 | 9.4 | Â |
High | 79 (9.2%) | 62.3 | 11.2 | Â |
Mucinous component | Â | Â | Â | 0.002 |
0% | 554 (65%) | 60.7 | 9.3 | Â |
1-49% | 188 (22%) | 61.3 | 10.0 | Â |
≥50% | 115 (13%) | 64.1 | 9.3 |  |
Signet ring cell component | Â | Â | Â | 0.009 |
0% | 796 (93%) | 61.0 | 9.4 | Â |
1-49% | 48 (5.6%) | 63.5 | 10.8 | Â |
≥50% | 14 (1.6%) | 67.6 | 8.5 |  |
Crohn's-like reaction | Â | Â | Â | 0.002 |
Absent/mild | 684 (92%) | 61.1 | 9.5 | Â |
Moderate/severe | 62 (8.3%) | 65.2 | 9.6 | Â |
Peritumoral lymphocytic reaction | Â | Â | Â | 0.018 |
Absent/mild | 744 (89%) | 60.9 | 9.4 | Â |
Moderate/severe | 93 (11%) | 63.6 | 10.3 | Â |
Tumor infiltrating lymphocytes (TIL) | Â | Â | Â | 0.043 |
Absent/mild | 740 (89%) | 60.9 | 9.5 | Â |
Moderate/severe | 96 (11%) | 63.2 | 10.2 | Â |
MSI status | Â | Â | Â | < 0.0001 |
MSI-low/MSS | 728 (85%) | 60.7 | 9.5 | Â |
MSI-high | 124 (15%) | 64.7 | 8.9 | Â |
CIMP status | Â | Â | Â | < 0.0001 |
CIMP-0 | 408 (47%) | 60.2 | 9.8 | Â |
CIMP-low | 333 (38%) | 61.3 | 9.3 | Â |
CIMP-high | 128 (15%) | 65.1 | 8.3 | Â |
CIN status (in MSI-low/MSS cases) | Â | Â | Â | 0.0002 |
(-) | 142 (25%) | 63.7 | 9.6 | Â |
(+) | 436 (75%) | 60.3 | 9.0 | Â |
KRAS mutation | Â | Â | Â | 0.90 |
(-) | 538 (63%) | 61.3 | 9.6 | Â |
(+) | 319 (37%) | 61.2 | 9.4 | Â |
BRAF mutation | Â | Â | Â | 0.001 |
(-) | 728 (87%) | 60.8 | 9.3 | Â |
(+) | 108 (13%) | 64.2 | 10.2 | Â |
PIK3CA mutation | Â | Â | Â | 0.24 |
(-) | 646 (85%) | 61.1 | 9.7 | Â |
(+) | 118 (15%) | 62.2 | 9.3 | Â |
TP53 expression | Â | Â | Â | 0.096 |
(-) | 488 (57%) | 61.8 | 9.8 | Â |
(+) | 371 (43%) | 60.7 | 9.3 | Â |
CDKN1A (p21) | Â | Â | Â | 0.0002 |
Lost | 682 (81%) | 60.6 | 9.6 | Â |
Expressed | 158 (19%) | 63.7 | 9.0 | Â |
CTNNB1 (β-catenin) score* |  |  |  | 0.47 |
0-2 (inactive) | 482 (64%) | 61.4 | 9.8 | Â |
3-5 (active) | 273 (36%) | 60.9 | 9.3 | Â |
PTGS2 (COX-2) expression | Â | Â | Â | 0.98 |
(-) | 142 (16%) | 61.3 | 11.2 | Â |
(+) | 719 (84%) | 61.3 | 9.2 | Â |
FASN expression | Â | Â | Â | 0.16 |
(-) | 742 (88%) | 61.1 | 9.7 | Â |
(+) | 99 (12%) | 62.4 | 8.7 | Â |